0001562762-21-000415 | 10-Q | XBRL Viewer

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2021



	Option ‎Shares (thousands)	Weighted ‎average ‎exercise ‎price		Weighted ‎average ‎remaining ‎contractual ‎life (years)	Aggregate ‎intrinsic ‎value ‎(thousands)
Outstanding at December 31, 2020	9,746	$	41.33
Granted	1,925		67.68
Exercised	(1,746)		34.38
Forfeited	(521)		51.64
Outstanding at September 30, 2021	9,404	$	47.44	7.2	$	275,662
Exercisable at September 30, 2021	4,439	$	38.61	6.0	$	168,709
Expected to vest at September 30, 2021	4,965	$	55.34	8.2	$	106,953

Fair Value of Options Using Black Scholes Option Pricing Model


	Nine Months Ended
	September 30,
	2021			2020
Risk-free interest rate	0.40%	-	0.84%	0.23%	-	1.67%
Expected term (years)	4.8			4.9
Expected volatility	33.0%	-	34.0%	28.0%	-	37.0%
Expected dividend yield		—%			—%

Summary of Restricted Stock Unit Activity


	Restricted Stock ‎Units (thousands)	Weighted ‎average ‎grant date fair value ‎per share		Weighted ‎average ‎remaining ‎contractual ‎life (years)
Outstanding at December 31, 2020	3	$	58.69
Granted	23		74.87
Vested	—		—
Forfeited	—		—
Outstanding at September 30, 2021	26	$	72.81	9.0

Stock-based Compensation Schedule



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
Stock-based compensation expense	$	7,451	$	7,020	$	22,781	$	21,138
Net stock-based compensation capitalized into inventory		170		(13)		511		197
Total stock-based compensation cost	$	7,621	$	7,007	$	23,292	$	21,335

EQUITY (Tables)

9 Months Ended

Sep. 30, 2021

EQUITY [Abstract]

Schedule of Shares Repurchased

(In thousands except for per share prices)


Period	Total number of shares repurchased	Average Price Paid per Share		Dollar amount of shares repurchased ⁽¹⁾		Approximate dollar value of shares that may yet be purchased under the plan
January 1, 2020 - March 31, 2020	1,920	$	38.49	$	73,902	$	126,098
April 1, 2020 - June 30, 2020	771		39.95		30,804		95,294
July 1, 2020 - September 30,2020	—		—		—		95,294
October 1, 2020 - December 31, 2020	—		—		—		95,294
January 1, 2021 - March 31, 2021	—		—		—		95,294
April 1, 2021 - June 30, 2021	—		—		—		95,294
July 1, 2021 - September 30, 2021	—		—		—	$	95,294
January 1, 2020 - September 30, 2021	2,691	$	38.91	$	104,706

⁽¹⁾ Inclusive of an immaterial amount of commission fees

Accumulated Other Comprehensive Income (Loss)



(In thousands)	Unrealized ‎gain/(loss) on ‎marketable ‎securities, ‎net of tax		Foreign ‎currency ‎translation ‎adjustments		Accumulated other comprehensive income/(loss)
Accumulated other comprehensive income/(loss), net of tax, at December 31, 2020	$	5,001	$	(1,046)	$	3,955
Other comprehensive income/(loss) before reclassifications		(4,179)		(3,578)		(7,757)
Amounts reclassified from accumulated other comprehensive income/(loss), net of tax		748		—		748
Other comprehensive income/(loss), net of tax		(3,431)		(3,578)		(7,009)
Accumulated other comprehensive income/(loss), net of tax, at September 30, 2021	$	1,570	$	(4,624)	$	(3,054)



(In thousands)	Unrealized ‎gain/(loss) on ‎marketable ‎securities, ‎net of tax		Foreign ‎currency ‎translation ‎adjustments		Accumulated ‎other ‎comprehensive income/(loss)
Accumulated other comprehensive income/(loss), net of tax, at December 31, 2019	$	3,599	$	(6,497)	$	(2,898)
Other comprehensive income/(loss) before reclassifications		3,001		2,820		5,821
Amounts reclassified from accumulated other comprehensive income/(loss), net of tax		(716)		—		(716)
Other comprehensive income/(loss), net of tax		2,285		2,820		5,105
Accumulated other comprehensive income/(loss), net of tax, at September 30, 2020	$	5,884	$	(3,677)	$	2,207

Schedule of Computation of Basic and Diluted Earnings


		Three Months Ended			Nine Months Ended
		September 30,			September 30,
(In thousands, except per share amounts)	2021		2020		2021		2020
Numerator:
Net income/(loss)	$	47,211	$	44,216	$	134,085	$	49,328
Denominator for basic and diluted net income per share:
Weighted average shares outstanding for basic		101,104		98,217		100,477		98,453
Dilutive stock options and RSUs		3,314		2,268		2,953		2,370
Weighted average shares outstanding for diluted		104,418		100,485		103,430		100,823
Earnings per share:
Basic	$	0.47	$	0.45	$	1.33	$	0.50
Diluted	$	0.45	$	0.44	$	1.30	$	0.49

Anti-dilutive stock options and RSUs excluded from the calculation		1,748		5,101		2,164		6,130

FAIR VALUE MEASUREMENTS (Fair Value of Assets and Liabilities Measured on Recurring Basis) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition liabilities	$ 57,842	$ 47,995	$ 37,270	$ 4,548	$ 4,216	$ 9,549
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	42,561		56,223
Business acquisition liabilities	57,842		37,270
Fair Value, Measurements, Recurring [Member] \| Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	126,120		110,612
Fair Value, Measurements, Recurring [Member] \| Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	313,998		260,334
Fair Value, Measurements, Recurring [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	16,994		25,547
Fair Value, Measurements, Recurring [Member] \| Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	155,913		141,426
Fair Value, Measurements, Recurring [Member] \| Government, Federal Agency, And Other Sovereign Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	10,108		7,947
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	38,386		23,628
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	4,175		32,595
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	126,120		110,612
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	313,998		260,334
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	16,994		25,547
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	155,913		141,426
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Government, Federal Agency, And Other Sovereign Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Securities	10,108		7,947
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition liabilities	$ 57,842		$ 37,270

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2021

FAIR VALUE MEASUREMENTS [Abstract]

Fair Value of Assets and Liabilities Measured on Recurring Basis



(In thousands)	Balance at September 30, 2021		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	42,561	$	38,386	$	4,175	$	—
Municipal bonds		126,120		—		126,120		—
Corporate debt securities		313,998		—		313,998		—
Commercial paper		16,994		—		16,994		—
Asset-backed securities		155,913		—		155,913		—
Government, federal agency, and other sovereign obligations		10,108		—		10,108		—
Liabilities:
Business acquisition liabilities		57,842		—		—		57,842



(In thousands)	Balance at December 31, 2020		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	56,223	$	23,628	$	32,595	$	—
Municipal bonds		110,612		—		110,612		—
Corporate debt securities		260,334		—		260,334		—
Commercial paper		25,547		—		25,547		—
Asset-backed securities		141,426		—		141,426		—
Government, federal agency, and other sovereign obligations		7,947		—		7,947		—
Liabilities:
Business acquisition liabilities		37,270		—		—		37,270

Significant Unobservable Inputs in Valuation Techniques


Unobservable input	Range			Weighted Average*
Revenue risk premium	2.5%	-	4.9%	3.1%
Revenue volatility	14.0%	-	15.8%	14.6%
Discount rate	1.0%	-	8.5%	3.3%
Projected year of payment	2021	-	2031

* The weighted average rates were calculated based on the relative fair value of each business acquisition liability.

Changes in Carrying Value of Business Acquisition Liabilities



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
Fair value measurement at beginning of period	$	47,995	$	4,216	$	37,270	$	9,549
Purchase price contingent consideration		12,628		—		12,628		—
Contingent cash payments		(1,613)		(175)		(4,628)		(1,028)
Contingent RSU grants		(1,311)		—		(1,671)		—
Changes in fair value of business acquisition liabilities		208		507		14,336		970
Contractual payable reclassification		(65)		—		(93)		(4,943)
Fair value measurement at September 30, 2021 and 2020, respectively	$	57,842	$	4,548	$	57,842	$	4,548

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash, cash equivalents, and restricted cash	$ 361,876	$ 239,397
Short-term marketable securities	191,319	187,344
Accounts receivable, net of allowances of $4,930 and $4,408, respectively	159,576	141,676
Inventories	234,368	229,153
Prepaid expenses and other current assets	16,207	17,771
Income taxes receivable	17,168	6,424
Total current assets	980,514	821,765
Property and equipment, net of accumulated depreciation of $301,163 and $276,451, respectively	215,665	216,879
Long-term marketable securities	431,814	358,522
Intangible assets, net	73,095	86,949
Goodwill	166,578	156,716
Other assets	33,574	32,039
Deferred income taxes	9,338	6,615
Total assets	1,910,578	1,679,485
Current liabilities:
Accounts payable	20,678	18,205
Accrued expenses	81,480	78,334
Income taxes payable	1,971	1,101
Business acquisition liabilities	8,729	5,777
Deferred revenue	9,667	8,125
Payable to broker		9,250
Total current liabilities	122,525	120,792
Business acquisition liabilities, net of current portion	49,113	31,493
Deferred income taxes	4,792	6,202
Other liabilities	15,879	14,701
Total liabilities	192,309	173,188
Commitments and contingencies (Note 15)
Equity:
Additional paid-in capital	542,055	457,161
Accumulated other comprehensive income (loss)	(3,054)	3,955
Retained earnings	1,179,167	1,045,082
Total equity	1,718,269	1,506,297
Total liabilities and equity	1,910,578	1,679,485
Common Class A [Member]
Equity:
Common stock	79	77
Common Class B [Member]
Equity:
Common stock	$ 22	$ 22

ACCRUED EXPENSES

9 Months Ended

Sep. 30, 2021

ACCRUED EXPENSES [Abstract]

Accrued Expenses

NOTE 10. ACCRUED EXPENSES

Accrued expense included the following:



	September 30,		December 31,
(In thousands)	2021		2020
Compensation and other employee-related costs	$	48,672	$	44,948
Legal and other settlements and expenses		604		650
Accrued non-income taxes		5,659		4,952
Royalties		3,821		3,720
Rebates & Fees		7,759		8,011
Other		14,965		16,053
Total accrued expenses	$	81,480	$	78,334

SUBSEQUENT EVENT (Details) - Subsequent Event [Member] - Capstone Surgical Technologies, LLC [Member] $ in Millions	Nov. 04, 2021 USD ($)
Subsequent Event [Line Items]
Purchase price, initial cash payment	$ 25.0
Maximum [Member]
Subsequent Event [Line Items]
Contingent consideration liability	$ 25.0

LEASES (Schedule of Supplemental Balance Sheet Information Related to Leases) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
LEASES [Abstract]
Operating lease right of use asset	$ 5,393	$ 4,741
Lease liability - current	2,128	1,865
Lease liability - long-term	3,297	2,936
Total operating lease liability	$ 5,425	$ 4,801
Weighted-average remaining lease term (years) - operating leases	3 years 1 month 6 days	2 years 10 months 24 days
Weighted-average discount rate - operating leases	3.30%	3.00%

LEASES (Tables)

9 Months Ended

Sep. 30, 2021

LEASES [Abstract]

Schedule of Supplemental Balance Sheet Information Related to Leases


	September 30,		December 31,
(In thousands, except weighted average lease term and discount rate)	2021		2020
Operating lease right of use asset	$	5,393	$	4,741

Lease liability - current		2,128		1,865
Lease liability - long-term		3,297		2,936
Total operating lease liability	$	5,425	$	4,801

Supplemental non-cash information:
Weighted-average remaining lease term (years) - operating leases		3.1		2.9
Weighted-average discount rate - operating leases		3.3%		3.0%

Operating Lease Expense Recognized


	Three months ended				Nine months ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
Operating lease expense	$	783	$	904	$	2,461	$	2,652

Future Minimum Lease Payments


(In thousands)	Operating Leases
Remaining 2021	$	607
2022		2,169
2023		1,452
2024		987
2025		396
Thereafter		153
Total undiscounted operating lease payments	$	5,764
Less: imputed interest		339
Total operating lease liability	$	5,425

FAIR VALUE MEASUREMENTS (Changes in Carrying Value of Business Acquisition Liabilities) (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value measurement, beginning balance	$ 47,995	$ 4,216	$ 37,270	$ 9,549
Purchase price contingent consideration	12,628		12,628
Contingent cash payments	(1,613)	(175)	(4,628)	(1,028)
Contingent RSU grants	(1,311)		(1,671)
Changes in fair value of business acquisition liabilities	208	507	14,336	970
Contractual payable reclassification	65		93	4,943
Fair value measurement, ending balance	$ 57,842	$ 4,548	$ 57,842	$ 4,548

GOODWILL AND INTANGIBLE ASSETS (Summary of Intangible Assets) (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 141,815	$ 143,430
Accumulated amortization	(68,720)	(56,481)
Intangible Assets, net	$ 73,095	$ 86,949
Supplier Network [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average amortization period	10 years	10 years
Gross Carrying Amount	$ 4,000	$ 4,000
Accumulated amortization	(2,767)	(2,467)
Intangible Assets, net	$ 1,233	$ 1,533
Customer Relationships & Other Intangibles [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average amortization period	6 years 6 months	6 years 6 months
Gross Carrying Amount	$ 57,090	$ 57,704
Accumulated amortization	(36,724)	(32,056)
Intangible Assets, net	$ 20,366	$ 25,648
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average amortization period	8 years	8 years
Gross Carrying Amount	$ 71,815	$ 72,644
Accumulated amortization	(26,152)	(19,295)
Intangible Assets, net	$ 45,663	$ 53,349
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted average amortization period	16 years 1 month 6 days	16 years 1 month 6 days
Gross Carrying Amount	$ 8,910	$ 9,082
Accumulated amortization	(3,077)	(2,663)
Intangible Assets, net	$ 5,833	$ 6,419

PROPERTY AND EQUIPMENT (Schedule of Depreciation Related to Property and Equipment) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
PROPERTY AND EQUIPMENT [Abstract]
Depreciation	$ 12,178	$ 12,148	$ 39,068	$ 33,925

ASSET ACQUISITIONS AND BUSINESS COMBINATIONS

9 Months Ended

Sep. 30, 2021

ASSET ACQUISITIONS AND BUSINESS COMBINATIONS [Abstract]

Asset Acquisitions And Business Combinations

NOTE 3. ASSET ACQUISITIONS AND BUSINESS COMBINATIONS

Asset Acquisitions

During the second quarter of 2020, the Company acquired Synoste Oy (“Synoste”), a Finnish engineering company that specializes in the research and development of a limb lengthening system. The fair value of the net assets acquired was $25.3 million, and the consideration consisted of approximately $22.8 million of cash paid at closing plus $2.5 million of a contractual holdback obligation payable eighteen months from the closing date of the transaction, subject to net working capital and other post-closing adjustments, if applicable. The contractual holdback obligation is included in accrued expenses in the condensed consolidated balance sheet.

The Company accounted for the transaction as an asset acquisition as substantially all of the fair value of the assets acquired was concentrated in a single identified asset, IPR&D of the limb lengthening system, thus satisfying the requirements of the screen test in ASU 2017-1. At the date of acquisition, the Company determined that the development of the projects underway at Synoste had not yet reached technological feasibility and that the research in process had no alternative future use. Accordingly, the acquired IPR&D of $24.4 million was charged to research and development expense in the condensed consolidated statements of operations and comprehensive income at the date of acquisition.

The transaction also provides for additional consideration contingent upon the developed product obtaining approval from the U.S. Food and Drug Administration (the “FDA”) of $8.0 million within the third anniversary, or $4.0 million within the fourth anniversary of the acquisition closing date, respectively. Contingent consideration is not recorded in an asset acquisition until the milestone is met.

Business Combinations

During the third quarter of 2021, the Company completed two acquisitions that were not considered material, individually or collectively, to the condensed consolidated financial statements during the periods presented. These acquisitions have been included in the condensed consolidated financial statements from the date of acquisition. The combined purchase price consisted of approximately $12.6 million of contingent consideration payments. The contingent payments are based upon achieving various performance obligations over a period of 10 years, and are payable in a combination of cash and RSUs. The Company recorded other intangible assets of $1.6 million, with a weighted average useful life of 3.8 years, and goodwill of $11.0 million based on their preliminary estimated fair values. The Company will finalize the purchase price allocation of the assets and liabilities acquired within one year from the date of acquisition. While the Company does not expect material changes from the initial outcome of the valuation, certain assumptions and findings made at the date of acquisition could result in changes in the purchase price allocation.

During the fourth quarter of 2020, the Company completed two acquisitions that were not considered material, individually or collectively, to the condensed consolidated financial statements during the periods presented. These acquisitions have been included in the condensed consolidated financial statements from the date of acquisition. The combined purchase price consisted of approximately $1.5 million of cash paid at closing, plus $0.3 million of other liabilities and $33.2 million of contingent consideration payments. The contingent payments are based upon achieving various performance obligations over a period of 10 years, and are payable in a

combination of cash and RSUs. The Company recorded other intangible assets of $8.8 million, with a weighted average useful life of 4.2 years, and goodwill of $26.2 million based on their fair values.

During the second quarter of 2019, the Company acquired substantially all of the assets of StelKast, Inc. (the “StelKast Acquisition”), a privately held company that designs, manufactures and distributes orthopedic implants for knee and hip replacement surgeries. The Company has included the financial results from the StelKast Acquisition in our condensed consolidated financial statements from the acquisition date. At the acquisition date, the fair value of the net assets acquired was $28.1 million. The purchase price consisted of approximately $23.8 million of cash paid at closing, plus $4.3 million of contingent consideration payable based upon the achievement of product sales milestones. The Company recorded identifiable net assets, based on their estimated fair values, for inventory of $15.3 million, fixed assets of $4.2 million and customer relationships of $3.9 million and goodwill of $4.7 million.

The contingent consideration payable related to the StelKast Acquisition of $5.0 million was paid during the third quarter of 2020.

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net income	$ 134,085	$ 49,328
Adjustments to reconcile net income to net cash provided by operating activities:
Acquired in-process research and development		24,418
Depreciation and amortization	53,038	45,970
Amortization of premium (discount) on marketable securities	1,763	215
Write-down of excess and obsolete inventories	5,570	12,411
Stock-based compensation expense	22,781	21,138
Allowance for doubtful accounts	883	2,741
Change in fair value of business acquisition liabilities	14,336	1,027
Change in deferred income taxes	(3,131)	(4,458)
(Gain)/loss on disposal of assets, net	383	714
Payment of business acquisition related liabilities		(700)
(Increase)/decrease in:
Accounts receivable	(19,928)	8,412
Inventories	(9,161)	(47,271)
Prepaid expenses and other assets	(794)	(4,381)
Increase/(decrease) in:
Accounts payable	2,521	5,401
Accrued expenses and other liabilities	7,500	3,749
Income taxes payable/receivable	(9,825)	(105)
Net cash provided by/(used in) operating activities	200,021	118,609
Cash flows from investing activities:
Purchases of marketable securities	(347,057)	(57,418)
Maturities of marketable securities	171,886	100,830
Sales of marketable securities	82,882	39,944
Purchases of property and equipment	(39,853)	(49,595)
Acquisition of businesses, net of cash acquired, and purchases of intangible and other assets		(31,991)
Net cash provided by/(used in) investing activities	(132,142)	1,770
Cash flows from financing activities:
Payment of business acquisition related liabilities	(4,763)	(5,327)
Proceeds from exercise of stock options	59,933	44,121
Repurchase of common stock		(104,669)
Net cash provided by/(used in) financing activities	55,170	(65,875)
Effect of foreign exchange rates on cash	(570)	379
Net increase in cash, cash equivalents, and restricted cash	122,479	54,883
Cash, cash equivalents, and restricted cash at beginning of period	239,397	195,724
Cash, cash equivalents, and restricted cash at end of period	361,876	250,607
Supplemental disclosures of cash flow information:
Income taxes paid	39,450	19,328
Purchases of property and equipment included in accounts payable and accrued expenses	$ 3,491	$ 3,931

STOCK-BASED COMPENSATION (Stock-based Compensation Schedule) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
STOCK-BASED COMPENSATION [Abstract]
Stock-based compensation expense	$ 7,451	$ 7,020	$ 22,781	$ 21,138
Net stock-based compensation capitalized into inventory	170	(13)	511	197
Total stock-based compensation cost	$ 7,621	$ 7,007	$ 23,292	$ 21,335

INVENTORIES (Tables)

9 Months Ended

Sep. 30, 2021

INVENTORIES [Abstract]

Schedule of Inventory



	September 30,		December 31,
(In thousands)	2021		2020
Raw materials	$	44,038	$	39,646
Work in process		18,274		16,446
Finished goods		172,056		173,061
Total inventories	$	234,368	$	229,153

PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment	$ 516,828	$ 493,330
Less: accumulated depreciation	(301,163)	(276,451)
Total	215,665	216,879
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	8,308	8,322
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 44,497	33,825
Useful Life	31 years 6 months
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 112,776	102,553
Instruments [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 285,730	278,930
Useful Life	5 years
Modules and cases [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 43,422	41,919
Useful Life	5 years
Other Property and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 22,095	$ 27,781
Maximum [Member] \| Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Life	15 years
Maximum [Member] \| Other Property and Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Life	5 years
Minimum [Member] \| Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Life	5 years
Minimum [Member] \| Other Property and Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Life	3 years

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)

9 Months Ended

Sep. 30, 2021

SEGMENT AND GEOGRAPHIC INFORMATION [Abstract]

Schedule of Total Sales by Geographical Area



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
United States	$	198,172	$	182,104	$	606,608	$	465,705
International		31,549		33,994		101,473		89,892
Total net sales	$	229,721	$	216,098	$	708,081	$	555,597

INCOME TAXES (Narrative) (Details) $ in Thousands	9 Months Ended
INCOME TAXES (Narrative) (Details) $ in Thousands	Sep. 30, 2020 USD ($)
INCOME TAXES [Abstract]
Acquired in-process research and development	$ 24,418

ACCRUED EXPENSES (Schedule of Accrued Expenses) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
ACCRUED EXPENSES [Abstract]
Compensation and other employee-related costs	$ 48,672	$ 44,948
Legal and other settlements and expenses	604	650
Accrued non-income taxes	5,659	4,952
Royalties	3,821	3,720
Rebates & Fees	7,759	8,011
Other	14,965	16,053
Total accrued expenses	$ 81,480	$ 78,334

SEGMENT AND GEOGRAPHIC INFORMATION (Narrative) (Details)	9 Months Ended
	Sep. 30, 2021 segment
SEGMENT AND GEOGRAPHIC INFORMATION [Abstract]
Number of operating segments	1

NET SALES

9 Months Ended

Sep. 30, 2021

NET SALES [Abstract]

Net Sales

NOTE 4. NET SALES

The following table represents net sales by product category:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
Musculoskeletal Solutions	$	209,478	$	207,063	$	652,157	$	533,085
Enabling Technologies		20,243		9,035		55,924		22,512
Total net sales	$	229,721	$	216,098	$	708,081	$	555,597

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

SEGMENT AND GEOGRAPHIC INFORMATION

9 Months Ended

Sep. 30, 2021

SEGMENT AND GEOGRAPHIC INFORMATION [Abstract]

Segment and Geographic Information

NOTE 17. SEGMENT AND GEOGRAPHIC INFORMATION

Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We manage our business globally within one operating segment, and segment information is consistent with how the chief operating decision makers review the business, makes investing and resource allocation decisions and assesses operating performance.

The following table represents total net sales by geographic area, based on the location of the customer:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
United States	$	198,172	$	182,104	$	606,608	$	465,705
International		31,549		33,994		101,473		89,892
Total net sales	$	229,721	$	216,098	$	708,081	$	555,597

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

LEASES

9 Months Ended

Sep. 30, 2021

LEASES [Abstract]

Leases

NOTE 16. LEASES

The Company leases certain equipment, vehicles, and facilities under the terms of operating lease agreements. Our leases have initial lease terms ranging from one year to fourteen years. Certain leases contain options to extend the term beyond the initial lease termination date. We use judgment to determine whether it is reasonably possible that we will extend the lease beyond the initial term and the length of the possible extension. Leases that have terms of less than 12 months are treated as short-term and we do not recognize right of use assets or lease liabilities for such leases. We generally estimate discount rates using our incremental borrowing rate, and based on other information available, at commencement date of a lease when determining the present value of future payments as most of our leases do not provide an implicit rate.

The Company includes right-of-use assets in other assets, short-term lease liabilities in accrued expenses, and long-term lease liabilities in other liabilities on the condensed consolidated balance sheet. Lease expense is recognized, on a straight-line basis over the term of the lease, as a component of operating income on the condensed consolidated statement of operations and comprehensive income.

Amounts reported in the condensed consolidated balance sheet were as follows:


	September 30,		December 31,
(In thousands, except weighted average lease term and discount rate)	2021		2020
Operating lease right of use asset	$	5,393	$	4,741

Lease liability - current		2,128		1,865
Lease liability - long-term		3,297		2,936
Total operating lease liability	$	5,425	$	4,801

Supplemental non-cash information:
Weighted-average remaining lease term (years) - operating leases		3.1		2.9
Weighted-average discount rate - operating leases		3.3%		3.0%

Operating lease expense recognized in the condensed consolidated statement of operations and comprehensive income was as follows:


	Three months ended				Nine months ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
Operating lease expense	$	783	$	904	$	2,461	$	2,652

Future minimum lease payments under non-cancellable leases as of September 30, 2021 are as follows:


(In thousands)	Operating Leases
Remaining 2021	$	607
2022		2,169
2023		1,452
2024		987
2025		396
Thereafter		153
Total undiscounted operating lease payments	$	5,764
Less: imputed interest		339
Total operating lease liability	$	5,425

EQUITY (Schedule of Shares Repurchased) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands

3 Months Ended

21 Months Ended

Jun. 30, 2020

Mar. 31, 2020

Sep. 30, 2021

Jun. 30, 2021

Mar. 31, 2021

Dec. 31, 2020

Sep. 30, 2020

EQUITY [Abstract]

Total number of shares repurchased

771

1,920

2,691

Average Price Paid per Share

$ 39.95

$ 38.49

$ 38.91

Dollar amount of shares repurchased

^[1]

$ 30,804

$ 73,902

$ 104,706

Approximate dollar value of shares that may yet be purchased under the plan

$ 95,294

$ 126,098

$ 95,294

[1]	Inclusive of an immaterial amount of commission fees

BACKGROUND	9 Months Ended
BACKGROUND	Sep. 30, 2021
BACKGROUND [Abstract]
Background	NOTE 1. BACKGROUND (a) The Company Globus Medical, Inc., together with its subsidiaries, is a medical device company that develops and commercializes healthcare solutions with a mission to improve the quality of life of patients with musculoskeletal disorders. We are primarily focused on implants that promote healing in patients with musculoskeletal disorders, including the use of a robotic guidance and navigation system and products to treat patients who have experienced orthopedic traumas. We are an engineering-driven company with a history of rapidly developing and commercializing advanced products and procedures to assist surgeons in effectively treating their patients and to address new treatment options. With over 220 product launches to date, we offer a comprehensive portfolio of innovative and differentiated technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. We are headquartered in Audubon, Pennsylvania, and we market and sell our products through our exclusive sales force in the United States, as well as within North, Central & South America, Europe, Asia, Africa and Australia. Our sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors. The terms the “Company,” “Globus,” “we,” “us” and “our” refer to Globus Medical, Inc. and, where applicable, our consolidated subsidiaries. (b) COVID-19 Pandemic Impact In March 2020, the World Health Organization declared the novel strain of coronavirus (“COVID-19”) a global pandemic and recommended containment and mitigation measures worldwide. COVID-19 has significantly impacted the economic conditions in the U.S. and globally as federal, state and local governments react to the public health crisis, creating significant uncertainties in the economy. Although the Company cannot reasonably estimate the length or severity of the impact that COVID-19 will have on its financial results, the Company may experience a material adverse impact on its sales, results of operations, and cash flows in 2021 should there be a resurgence impacting hospitals and surgical facilities to which we provide services. In response to these developments, the Company will continue to monitor liquidity and cash flow. The Company has the ability to borrow from its existing credit facility, if needed, although we do not expect to do so due to our cash, cash equivalents and short-term marketable securities balances.

STOCK-BASED COMPENSATION (Summary of Restricted Stock Unit Activity) (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands	9 Months Ended
	Sep. 30, 2021 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Beginning Balance \| shares	3
Granted \| shares	23
Outstanding, Ending Balance \| shares	26
Weighted average grant date fair value per share, Beginning Balance \| $ / shares	$ 58.69
Weighted average grant date fair value per share, Granted \| $ / shares	74.87
Weighted average grant date fair value per share, Ending Balance \| $ / shares	$ 72.81
Weighted average remaining contractual life (years)	9 years

NET SALES (Tables)

9 Months Ended

Sep. 30, 2021

NET SALES [Abstract]

Schedule of Net Sales by Product Category


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
Musculoskeletal Solutions	$	209,478	$	207,063	$	652,157	$	533,085
Enabling Technologies		20,243		9,035		55,924		22,512
Total net sales	$	229,721	$	216,098	$	708,081	$	555,597

EQUITY (Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity, beginning of period	$ 1,639,273	$ 1,336,915	$ 1,506,297	$ 1,402,452
Total other comprehensive income/(loss)	(1,482)	909	(7,009)	5,105
Total equity, end of period	1,718,269	1,417,204	1,718,269	1,417,204
Accumulated Other Comprehensive Income/(Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity, beginning of period	(1,572)	1,298	3,955	(2,898)
Other comprehensive income/(loss) before reclassifications			(7,757)	5,821
Amounts reclassified from accumulated other comprehensive income/(loss), net of tax			748	(716)
Total other comprehensive income/(loss)			(7,009)	5,105
Total equity, end of period	(3,054)	2,207	(3,054)	2,207
Unrealized Gain/(Loss) On Marketable Securities, Net Of Tax [Member] \| Accumulated Other Comprehensive Income/(Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity, beginning of period			5,001	3,599
Other comprehensive income/(loss) before reclassifications			(4,179)	3,001
Amounts reclassified from accumulated other comprehensive income/(loss), net of tax			748	(716)
Total other comprehensive income/(loss)			(3,431)	2,285
Total equity, end of period	1,570	5,884	1,570	5,884
Foreign Currency Translation Adjustments [Member] \| Accumulated Other Comprehensive Income/(Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity, beginning of period			(1,046)	(6,497)
Other comprehensive income/(loss) before reclassifications			(3,578)	2,820
Total other comprehensive income/(loss)			(3,578)	2,820
Total equity, end of period	$ (4,624)	$ (3,677)	$ (4,624)	$ (3,677)

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	Sep. 30, 2021 USD ($)
Moskowitz Family LLC Litigation [Member]
Estimated Litigation Liability	$ 0

PROPERTY AND EQUIPMENT (Tables)

9 Months Ended

Sep. 30, 2021

PROPERTY AND EQUIPMENT [Abstract]

Schedule of Property and Equipment



	Useful	September 30,		December 31,
(In thousands)	Life	2021		2020
Land	—	$	8,308	$	8,322
Buildings and improvements	31.5		44,497		33,825
Equipment	5-15		112,776		102,553
Instruments	5		285,730		278,930
Modules and cases	5		43,422		41,919
Other property and equipment	3-5		22,095		27,781
			516,828		493,330
Less: accumulated depreciation			(301,163)		(276,451)
Total		$	215,665	$	216,879

Schedule of Depreciation Related to Property and Equipment



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
Depreciation	$	12,178	$	12,148	$	39,068	$	33,925

INVENTORIES (Schedule of Inventory) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
INVENTORIES [Abstract]
Raw materials	$ 44,038	$ 39,646
Work in process	18,274	16,446
Finished goods	172,056	173,061
Total inventories	$ 234,368	$ 229,153

EQUITY (Narrative) (Details) $ in Thousands	9 Months Ended
EQUITY (Narrative) (Details) $ in Thousands	Sep. 30, 2021 USD ($) item / shares item shares	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($) shares	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Mar. 11, 2020 USD ($)
Class of Stock [Line Items]
Stock repurchase plan, authorized amount \| $								$ 200,000
Stock repurchase plan, remaining authorized amount \| $	$ 95,294	$ 95,294	$ 95,294	$ 95,294	$ 95,294	$ 95,294	$ 126,098
Common stock, shares authorized	775,000,000
Common Class A [Member]
Class of Stock [Line Items]
Common stock, shares authorized	500,000,000			500,000,000
Number of votes per share \| item / shares	1
Common Class A And B [Member]
Class of Stock [Line Items]
Number of votes per share \| item	1
Common Class B [Member]
Class of Stock [Line Items]
Common stock, shares authorized	275,000,000			275,000,000
Number of votes per share \| item / shares	10
Conversion of stock shares converted ratio	1

INCOME TAXES (Reconciliation of Statutory U.S. Federal Tax Rate to Effective Rate) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
INCOME TAXES [Abstract]
Effective income tax rate	13.30%	16.80%	16.50%	22.50%

EQUITY (Schedule Of Computation of Basic and Diluted Earnings) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
EQUITY [Abstract]
Net income/(loss)	$ 47,211	$ 44,216	$ 134,085	$ 49,328
Weighted average shares outstanding for basic	101,104	98,217	100,477	98,453
Dilutive stock options and RSUs	3,314	2,268	2,953	2,370
Weighted average shares outstanding for diluted	104,418	100,485	103,430	100,823
Basic	$ 0.47	$ 0.45	$ 1.33	$ 0.50
Diluted	$ 0.45	$ 0.44	$ 1.30	$ 0.49
Anti-dilutive stock options and RSUs excluded from the calculation	1,748	5,101	2,164	6,130

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Accounts receivable, allowances	$ 4,930	$ 4,408
Property and equipment
Accumulated depreciation	$ 301,163	$ 276,451
Equity:
Common stock, shares authorized	775,000,000
Common Class A [Member]
Equity:
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	79,029,625	77,284,007
Common stock, shares outstanding	79,029,625	77,284,007
Common Class B [Member]
Equity:
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	275,000,000	275,000,000
Common stock, shares issued	22,430,097	22,430,097
Common stock, shares outstanding	22,430,097	22,430,097

MARKETABLE SECURITIES (Tables)

9 Months Ended

Sep. 30, 2021

MARKETABLE SECURITIES [Abstract]

Composition of Marketable Securities

The composition of our short-term and long-term marketable securities was as follows:



	September 30, 2021
(In thousands)	Amortized ‎Cost		Gross ‎Unrealized ‎Gains		Gross Unrealized Losses		Fair ‎Value
Short-term:
Municipal bonds	$	59,492	$	205	$	(1)	$	59,696
Corporate debt securities		87,754		766		—		88,520
Commercial paper		16,990		4		—		16,994
Asset-backed securities		15,880		121		—		16,001
Government, federal agency, and other sovereign obligations		10,106		2		—		10,108
Total short-term marketable securities	$	190,222	$	1,098	$	(1)	$	191,319

Long-term:
Municipal bonds	$	66,306	$	139	$	(21)	$	66,424
Corporate debt securities		224,466		1,063		(51)		225,478
Asset-backed securities		139,778		276		(142)		139,912
Total long-term marketable securities	$	430,550	$	1,478	$	(214)	$	431,814



	December 31, 2020
(In thousands)	Amortized ‎Cost		Gross ‎Unrealized ‎Gains		Gross ‎Unrealized ‎Losses		Fair ‎Value
Short-term:
Municipal bonds	$	39,684	$	140	$	—	$	39,824
Corporate debt securities		97,937		817		(4)		98,750
Commercial paper		25,543		4		—		25,547
Asset-backed securities		15,232		44		—		15,276
Government, federal agency, and other sovereign obligations		7,886		61		—		7,947
Total short-term marketable securities	$	186,282	$	1,066	$	(4)	$	187,344

Long-term:
Municipal bonds	$	70,176	$	612	$	—	$	70,788
Corporate debt securities		158,464		3,120		—		161,584
Asset-backed securities		124,406		1,747		(3)		126,150
Total long-term marketable securities	$	353,046	$	5,479	$	(3)	$	358,522

SUBSEQUENT EVENT

9 Months Ended

Sep. 30, 2021

SUBSEQUENT EVENT [Abstract]

Subsequent Event

NOTE 18. SUBSEQUENT EVENT

On November 4, 2021, the Company acquired substantially all of the assets of Capstone Surgical Technologies, LLC, which engages in the business of creating advanced drill and robotic surgery platforms. The purchase price is a combination of an initial cash payment of $25.0 million, subject to post-closing adjustments, if applicable, and contingent consideration of up to $25.0 million.

INVENTORIES (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
INVENTORIES (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
INVENTORIES [Abstract]
Net adjustment to cost of sales related to excess and obsolete inventory	$ 0.6	$ 5.2	$ 5.6	$ 12.4
Excess and obsolete related provisions	3.8	7.9	15.2	18.9
Inventory sales and disposals related provisions	$ 3.2	$ 2.7	$ 9.6	$ 6.5

MARKETABLE SECURITIES (Composition of Marketable Securities) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 190,222	$ 186,282
Gross Unrealized Gains	1,098	1,066
Gross Unrealized Losses	(1)	(4)
Fair Value	191,319	187,344
Short-term Investments [Member] \| Municipal Bonds [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	59,492	39,684
Gross Unrealized Gains	205	140
Gross Unrealized Losses	(1)
Fair Value	59,696	39,824
Short-term Investments [Member] \| Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	87,754	97,937
Gross Unrealized Gains	766	817
Gross Unrealized Losses		(4)
Fair Value	88,520	98,750
Short-term Investments [Member] \| Commercial Paper [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	16,990	25,543
Gross Unrealized Gains	4	4
Fair Value	16,994	25,547
Short-term Investments [Member] \| Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	15,880	15,232
Gross Unrealized Gains	121	44
Fair Value	16,001	15,276
Short-term Investments [Member] \| Government, Federal Agency, And Other Sovereign Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	10,106	7,886
Gross Unrealized Gains	2	61
Fair Value	10,108	7,947
Long-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	430,550	353,046
Gross Unrealized Gains	1,478	5,479
Gross Unrealized Losses	(214)	(3)
Fair Value	431,814	358,522
Long-term Investments [Member] \| Municipal Bonds [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	66,306	70,176
Gross Unrealized Gains	139	612
Gross Unrealized Losses	(21)
Fair Value	66,424	70,788
Long-term Investments [Member] \| Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	224,466	158,464
Gross Unrealized Gains	1,063	3,120
Gross Unrealized Losses	(51)
Fair Value	225,478	161,584
Long-term Investments [Member] \| Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	139,778	124,406
Gross Unrealized Gains	276	1,747
Gross Unrealized Losses	(142)	(3)
Fair Value	$ 139,912	$ 126,150

NET SALES (Schedule of Net Sales by Product Category) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Net sales	$ 229,721	$ 216,098	$ 708,081	$ 555,597
Musculoskeletal Solutions [Member]
Disaggregation of Revenue [Line Items]
Net sales	209,478	207,063	652,157	533,085
Enabling Technologies [Member]
Disaggregation of Revenue [Line Items]
Net sales	$ 20,243	$ 9,035	$ 55,924	$ 22,512

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

MARKETABLE SECURITIES

9 Months Ended

Sep. 30, 2021

MARKETABLE SECURITIES [Abstract]

Marketable Securities

NOTE 5. MARKETABLE SECURITIES

The composition of our short-term and long-term marketable securities was as follows:



	September 30, 2021
(In thousands)	Amortized ‎Cost		Gross ‎Unrealized ‎Gains		Gross Unrealized Losses		Fair ‎Value
Short-term:
Municipal bonds	$	59,492	$	205	$	(1)	$	59,696
Corporate debt securities		87,754		766		—		88,520
Commercial paper		16,990		4		—		16,994
Asset-backed securities		15,880		121		—		16,001
Government, federal agency, and other sovereign obligations		10,106		2		—		10,108
Total short-term marketable securities	$	190,222	$	1,098	$	(1)	$	191,319

Long-term:
Municipal bonds	$	66,306	$	139	$	(21)	$	66,424
Corporate debt securities		224,466		1,063		(51)		225,478
Asset-backed securities		139,778		276		(142)		139,912
Total long-term marketable securities	$	430,550	$	1,478	$	(214)	$	431,814



	December 31, 2020
(In thousands)	Amortized ‎Cost		Gross ‎Unrealized ‎Gains		Gross ‎Unrealized ‎Losses		Fair ‎Value
Short-term:
Municipal bonds	$	39,684	$	140	$	—	$	39,824
Corporate debt securities		97,937		817		(4)		98,750
Commercial paper		25,543		4		—		25,547
Asset-backed securities		15,232		44		—		15,276
Government, federal agency, and other sovereign obligations		7,886		61		—		7,947
Total short-term marketable securities	$	186,282	$	1,066	$	(4)	$	187,344

Long-term:
Municipal bonds	$	70,176	$	612	$	—	$	70,788
Corporate debt securities		158,464		3,120		—		161,584
Asset-backed securities		124,406		1,747		(3)		126,150
Total long-term marketable securities	$	353,046	$	5,479	$	(3)	$	358,522

The short-term marketable securities have effective maturity dates of less than one year and the long-term marketable securities have effective maturity dates ranging from one to three years as of September 30, 2021 and December 31, 2020, respectively.

Purchases of marketable securities include amounts payable to brokers of $9.3 million as of December 31, 2020.

STOCK-BASED COMPENSATION (Summary of Stock Option Activity) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Option shares outstanding beginning balance	9,746
Option shares granted	1,925
Option shares exercised	(1,746)
Option shares forfeited	(521)
Option shares outstanding ending balance	9,404
Option shares exercisable	4,439
Option shares expected to vest	4,965
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted average exercise price per share outstanding beginning balance	$ 41.33
Weighted average exercise price per share granted	67.68
Weighted average exercise price per share exercised	34.38
Weighted average exercise price per share forfeited	51.64
Weighted average exercise price per share outstanding ending balance	47.44
Weighted average exercise price per share exercisable	38.61
Weighted average exercise price per share expected to vest	$ 55.34
Weighted average remaining contractual life outstanding	7 years 2 months 12 days
Weighted average remaining contractual life exercisable	6 years
Weighted average remaining contractual life expected to vest	8 years 2 months 12 days
Aggregate intrinsic value outstanding	$ 275,662
Aggregate intrinsic value exercisable	168,709
Aggregate intrinsic value expected to vest	$ 106,953

EQUITY

9 Months Ended

Sep. 30, 2021

EQUITY [Abstract]

Equity

NOTE 12. EQUITY

Stock Repurchases

Under the current stock repurchase plan, announced in March 2020, the Company is authorized to repurchase up to $200 million of the Company’s Class A common stock. The repurchase program has no time limit and may be suspended for periods or discontinued at any time. As of September 30, 2021, $95.3 million of this authorization is remaining. The timing and actual number of shares repurchased will depend on various factors including price, corporate and regulatory requirements, debt covenant requirements, alternative investment opportunities and other market conditions. Funding of share repurchases is expected to come from operating cash flows and excess cash.

Shares repurchased by the Company are accounted for under the constructive retirement method, in which the shares repurchased, are immediately retired, as there is no plan to reissue. The Company made an accounting policy election to charge the excess of repurchase price over par value entirely to retained earnings.

The following table summarizes the activity related to share repurchases:

(In thousands except for per share prices)


Period	Total number of shares repurchased	Average Price Paid per Share		Dollar amount of shares repurchased ⁽¹⁾		Approximate dollar value of shares that may yet be purchased under the plan
January 1, 2020 - March 31, 2020	1,920	$	38.49	$	73,902	$	126,098
April 1, 2020 - June 30, 2020	771		39.95		30,804		95,294
July 1, 2020 - September 30,2020	—		—		—		95,294
October 1, 2020 - December 31, 2020	—		—		—		95,294
January 1, 2021 - March 31, 2021	—		—		—		95,294
April 1, 2021 - June 30, 2021	—		—		—		95,294
July 1, 2021 - September 30, 2021	—		—		—	$	95,294
January 1, 2020 - September 30, 2021	2,691	$	38.91	$	104,706

⁽¹⁾ Inclusive of an immaterial amount of commission fees

Common Stock

Our amended and restated Certificate of Incorporation provides for a total of 775,000,000 authorized shares of common stock. Of the authorized number of shares of common stock, 500,000,000 shares are designated as Class A common stock (“Class A Common”), and 275,000,000 shares are designated as Class B common stock (“Class B Common”).

The holders of Class A Common are entitled to one vote for each share of Class A Common held. The holders of Class B Common are entitled to 10 votes for each share of Class B Common held. The holders of Class A Common and Class B Common vote together as one class of common stock on all matters submitted to a vote of stockholders, except as required by law or our amended and restated Certificate of Incorporation. Each share of our Class B common stock is convertible at any time at the option of the holder into one share of our Class A common stock. In addition, each share of our Class B common stock will convert automatically into one share of our Class A common stock upon any transfer, whether or not for value, except for permitted transfers. For more details relating to the conversion of our Class B common stock please see “Exhibit 4.2, Description of Securities of the Registrant” filed with our Annual Report on Form 10-K on February 17, 2021.

Accumulated Other Comprehensive Income (Loss)

The tables below present the changes in each component of accumulated other comprehensive income/(loss), including current period other comprehensive income/(loss) and reclassifications out of accumulated other comprehensive income/(loss) for the nine months ended September 30, 2021 and 2020, respectively:



(In thousands)	Unrealized ‎gain/(loss) on ‎marketable ‎securities, ‎net of tax		Foreign ‎currency ‎translation ‎adjustments		Accumulated other comprehensive income/(loss)
Accumulated other comprehensive income/(loss), net of tax, at December 31, 2020	$	5,001	$	(1,046)	$	3,955
Other comprehensive income/(loss) before reclassifications		(4,179)		(3,578)		(7,757)
Amounts reclassified from accumulated other comprehensive income/(loss), net of tax		748		—		748
Other comprehensive income/(loss), net of tax		(3,431)		(3,578)		(7,009)
Accumulated other comprehensive income/(loss), net of tax, at September 30, 2021	$	1,570	$	(4,624)	$	(3,054)



(In thousands)	Unrealized ‎gain/(loss) on ‎marketable ‎securities, ‎net of tax		Foreign ‎currency ‎translation ‎adjustments		Accumulated ‎other ‎comprehensive income/(loss)
Accumulated other comprehensive income/(loss), net of tax, at December 31, 2019	$	3,599	$	(6,497)	$	(2,898)
Other comprehensive income/(loss) before reclassifications		3,001		2,820		5,821
Amounts reclassified from accumulated other comprehensive income/(loss), net of tax		(716)		—		(716)
Other comprehensive income/(loss), net of tax		2,285		2,820		5,105
Accumulated other comprehensive income/(loss), net of tax, at September 30, 2020	$	5,884	$	(3,677)	$	2,207

Amounts reclassified from accumulated other comprehensive loss, net of tax, related to unrealized gains/losses on marketable securities were released to other income, net in our condensed consolidated statements of operations and comprehensive income.

Earnings Per Common Share

The Company computes basic earnings per share using the weighted-average number of common shares outstanding during the period. Diluted earnings per share assumes the conversion, exercise or issuance of all potential common stock equivalents, unless the effect of inclusion would be anti-dilutive. For purposes of this calculation, common stock equivalents include the Company’s stock options and unvested RSUs. The contingently issuable shares are included in basic net income per share as of the date that all necessary conditions have been satisfied and are included in the denominator for dilutive calculation for the entire period if such shares would be issuable as of the end of the reporting period assuming the end of the reporting period was the end of the contingency period.

The following table sets forth the computation of basic and diluted earnings per share:


		Three Months Ended			Nine Months Ended
		September 30,			September 30,
(In thousands, except per share amounts)	2021		2020		2021		2020
Numerator:
Net income/(loss)	$	47,211	$	44,216	$	134,085	$	49,328
Denominator for basic and diluted net income per share:
Weighted average shares outstanding for basic		101,104		98,217		100,477		98,453
Dilutive stock options and RSUs		3,314		2,268		2,953		2,370
Weighted average shares outstanding for diluted		104,418		100,485		103,430		100,823
Earnings per share:
Basic	$	0.47	$	0.45	$	1.33	$	0.50
Diluted	$	0.45	$	0.44	$	1.30	$	0.49

Anti-dilutive stock options and RSUs excluded from the calculation		1,748		5,101		2,164		6,130

STOCK-BASED COMPENSATION (Narrative) (Details) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021 USD ($) ShareBasedCompensationPlan $ / shares shares	Sep. 30, 2020 USD ($) $ / shares	Sep. 30, 2021 USD ($) ShareBasedCompensationPlan $ / shares shares	Sep. 30, 2020 USD ($) $ / shares	Mar. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock plans \| ShareBasedCompensationPlan	3		3
Intrinsic value of stock options exercised \| $	$ 33.8	$ 23.3	$ 68.9	$ 39.4
Weighted average grant date fair value per share \| $ / shares	$ 24.11	$ 16.98	$ 20.19	$ 14.54
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			4 years
Unrecognized compensation expense, unvested stock options \| $	$ 66.1		$ 66.1
Weighted average period of recognition, unvested stock options			3 years
Maximum contractual term			10 years
2012 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Base number of shares that may be issuable under stock plan	3,076,923		3,076,923
2012 Equity Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class A number of shares available for grant under the 2012 Equity Incentive Plan	10,769,230		10,769,230
Annual percentage limit for incremental shares that may be issued					3.00%
2021 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	2,000,000		2,000,000
2021 Plan [Member] \| Common Class A [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved	2,845,575		2,845,575
Class A number of shares available for grant under the 2012 Equity Incentive Plan	2,684,008		2,684,008

GOODWILL AND INTANGIBLE ASSETS (Schedule of Finite-Lived Intangible Assets, Future Amortization Expense) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
GOODWILL AND INTANGIBLE ASSETS [Abstract]
Remaining 2021	$ 4,602
2022	18,260
2023	16,157
2024	13,162
2025	8,876
Thereafter	12,038
Intangible Assets, net	$ 73,095	$ 86,949

LEASES (Narrative) (Details)	9 Months Ended
LEASES (Narrative) (Details)	Sep. 30, 2021
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lease term	14 years
Lease term that are not recognized as right of use assets or lease liabilities	12 months
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lease term	1 year

SEGMENT AND GEOGRAPHIC INFORMATION (Schedule of Total Sales by Geographical Area) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	$ 229,721	$ 216,098	$ 708,081	$ 555,597
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	198,172	182,104	606,608	465,705
International [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	$ 31,549	$ 33,994	$ 101,473	$ 89,892

- Definition

+ References

+ Details

INCOME TAXES

9 Months Ended

Sep. 30, 2021

INCOME TAXES [Abstract]

Income Taxes

NOTE 14. INCOME TAXES

In computing our income tax provision, we make certain estimates and judgments, such as estimated annual taxable income or loss, annual effective tax rate, the nature and timing of permanent and temporary differences between taxable income for financial reporting and tax reporting, and the recoverability of deferred tax assets. Our estimates and assumptions may change as new events occur, additional information is obtained, or as the tax environment changes. Should facts and circumstances change during a quarter causing a material change to the estimated effective income tax rate, a cumulative adjustment is recorded.

The following table provides a summary of our effective tax rate for the three and nine months ended September 30, 2021 and 2020, respectively:


	Three Months Ended		Nine Months Ended
	September 30,		September 30,
	2021	2020	2021	2020
Effective income tax rate	13.3%	16.8%	16.5%	22.5%

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Condensed Consolidated Statements of Equity - USD ($) shares in Thousands, $ in Thousands	Cumulative Effect Of Adoption Of Accouting Standards [Member] Retained Earnings [Member]	Cumulative Effect Of Adoption Of Accouting Standards [Member]	Common Stock [Member] Common Class A [Member]	Common Stock [Member] Common Class B [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income/(Loss) [Member]	Retained Earnings [Member]	Total
Shares, Outstanding, Beginning Balance at Dec. 31, 2019			77,394	22,431
Total equity, beginning of period at Dec. 31, 2019			$ 77	$ 22	$ 357,320	$ (2,898)	$ 1,047,931	$ 1,402,452
Stock-based compensation					6,902			6,902
Exercise of stock options (shares)			190
Exercise of stock options			$ 1		5,762			5,763
Comprehensive income/(loss)						(3,368)	25,949	22,581
Repurchase and retirement of common stock (shares)			(1,920)
Repurchase and retirement of common stock			$ (2)				(73,862)	(73,864)
Total equity, end of period at Mar. 31, 2020	$ (468)	$ (468)	$ 76	$ 22	369,984	(6,266)	999,550	1,363,366
Shares, Outstanding, Ending Balance at Mar. 31, 2020			75,664	22,431
Shares, Outstanding, Beginning Balance at Dec. 31, 2019			77,394	22,431
Total equity, beginning of period at Dec. 31, 2019			$ 77	$ 22	357,320	(2,898)	1,047,931	1,402,452
Comprehensive income/(loss)								54,433
Total equity, end of period at Sep. 30, 2020			$ 76	$ 22	422,774	2,207	992,125	1,417,204
Shares, Outstanding, Ending Balance at Sep. 30, 2020			76,242	22,430
Shares, Outstanding, Beginning Balance at Mar. 31, 2020			75,664	22,431
Total equity, beginning of period at Mar. 31, 2020	$ (468)	$ (468)	$ 76	$ 22	369,984	(6,266)	999,550	1,363,366
Stock-based compensation					7,426			7,426
Exercise of stock options (shares)			434
Exercise of stock options (shares)				(1)
Exercise of stock options					10,201			10,201
Comprehensive income/(loss)						7,564	(20,837)	(13,273)
Repurchase and retirement of common stock (shares)			(771)
Repurchase and retirement of common stock			$ (1)				(30,804)	(30,805)
Total equity, end of period at Jun. 30, 2020			$ 75	$ 22	387,611	1,298	947,909	1,336,915
Shares, Outstanding, Ending Balance at Jun. 30, 2020			75,327	22,430
Stock-based compensation					7,007			7,007
Exercise of stock options (shares)			915
Exercise of stock options			$ 1		28,156			28,157
Comprehensive income/(loss)						909	44,216	45,125
Total equity, end of period at Sep. 30, 2020			$ 76	$ 22	422,774	2,207	992,125	1,417,204
Shares, Outstanding, Ending Balance at Sep. 30, 2020			76,242	22,430
Shares, Outstanding, Beginning Balance at Dec. 31, 2020			77,284	22,430
Total equity, beginning of period at Dec. 31, 2020			$ 77	$ 22	457,161	3,955	1,045,082	1,506,297
Stock-based compensation					7,883			7,883
Grant of restricted stock units					163			163
Exercise of stock options (shares)			303
Exercise of stock options			$ 1		9,100			9,101
Comprehensive income/(loss)						(5,779)	45,329	39,550
Total equity, end of period at Mar. 31, 2021			$ 78	$ 22	474,307	(1,824)	1,090,411	1,562,994
Shares, Outstanding, Ending Balance at Mar. 31, 2021			77,587	22,430
Shares, Outstanding, Beginning Balance at Dec. 31, 2020			77,284	22,430
Total equity, beginning of period at Dec. 31, 2020			$ 77	$ 22	457,161	3,955	1,045,082	$ 1,506,297
Exercise of stock options (shares)								1,746
Comprehensive income/(loss)								$ 127,076
Total equity, end of period at Sep. 30, 2021			$ 79	$ 22	542,055	(3,054)	1,179,167	1,718,269
Shares, Outstanding, Ending Balance at Sep. 30, 2021			79,030	22,430
Shares, Outstanding, Beginning Balance at Mar. 31, 2021			77,587	22,430
Total equity, beginning of period at Mar. 31, 2021			$ 78	$ 22	474,307	(1,824)	1,090,411	1,562,994
Stock-based compensation					7,788			7,788
Grant of restricted stock units					197			197
Exercise of stock options (shares)			716
Exercise of stock options			$ 1		26,496			26,497
Comprehensive income/(loss)						252	41,545	41,797
Total equity, end of period at Jun. 30, 2021			$ 79	$ 22	508,788	(1,572)	1,131,956	1,639,273
Shares, Outstanding, Ending Balance at Jun. 30, 2021			78,303	22,430
Stock-based compensation					7,621			7,621
Grant of restricted stock units					1,311			1,311
Exercise of stock options (shares)			727
Exercise of stock options					24,335			24,335
Comprehensive income/(loss)						(1,482)	47,211	45,729
Total equity, end of period at Sep. 30, 2021			$ 79	$ 22	$ 542,055	$ (3,054)	$ 1,179,167	$ 1,718,269
Shares, Outstanding, Ending Balance at Sep. 30, 2021			79,030	22,430

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)	Sep. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, these condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position as of September 30, 2021, and results of operations for the three and nine months ended September 30, 2021. The results of operations for any interim period may not be indicative of results for the full year.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Globus and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are determined to be necessary. Significant areas that require estimates include revenue recognition, intangible assets, business acquisition liabilities, allowance for doubtful accounts, stock-based compensation, reserves for excess and obsolete inventory, useful lives of assets, the outcome of litigation, recoverability of intangible assets and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.
Revenue Recognition	Revenue Recognition Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Sales and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. For purposes of disclosure, we disaggregate our revenue into two categories, Musculoskeletal Solutions and Enabling Technologies. Our Musculoskeletal Solutions products consist primarily of the implantable devices, disposables, and unique instruments used in an expansive range of spine, orthopedic trauma, hip, knee and extremity procedures. The majority of contracts with our customers for Musculoskeletal Solutions products have a single performance obligation and revenue is recognized at a point in time. Our Enabling Technologies products are advanced robotics hardware systems and related technologies that are designed to enhance a surgeon’s capabilities and streamline surgical procedures by making them less invasive, more accurate, and more reproducible to improve patient care. The majority of contracts with our customers for Enabling Technologies products contain multiple performance obligations, including maintenance and support, and revenue is recognized as we fulfill each performance obligation. When contracts have multiple performance obligations, we allocate the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold. Nature of Products and Services A significant portion of our Musculoskeletal Solutions product revenue is generated from consigned inventory maintained at hospitals or with sales representatives. Revenue from the sale of consigned musculoskeletal products is recognized when we transfer control, which generally occurs at the time the product is used or implanted. For all other Musculoskeletal Solutions product transactions, we recognize revenue when we transfer title to the goods, provided there are no remaining performance obligations that can affect the customer’s final acceptance of the sale. Revenue from the sale of Enabling Technologies products is generally recognized when control transfers to the customer which occurs at the time the product is shipped or delivered. Any revenue related to the provision of maintenance and support is recognized as we satisfy the performance obligation. We use an observable price to determine the stand-alone selling price for each separate performance obligation. Contract Balances Timing of revenue recognition may differ from the timing of invoicing to customers. We record a receivable when revenue is recognized prior to invoicing, or deferred revenue when revenue is recognized subsequent to invoicing. Deferred revenue is comprised mainly of unearned revenue related to the sales of certain Enabling Technologies products, which includes maintenance and support services. Maintenance and support services are generally invoiced annually, at the beginning of each contract period, and revenue is recognized ratably over the maintenance period. For the three and nine months ended September 30, 2021, there was an immaterial amount of revenue recognized from previously deferred revenue.
Cash, Cash Equivalents, and Restricted Cash	Cash, Cash Equivalents, and Restricted Cash The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. Cash equivalents, which consist of money market accounts, commercial paper and corporate debt securities are stated at fair value.
Marketable Securities	Marketable Securities Our marketable securities include municipal bonds, corporate debt securities, commercial paper, asset-backed securities, and securities of government, federal agency, and other sovereign obligations are classified as available-for-sale as of September 30, 2021. Short-term and long-term marketable securities are recorded at fair value on our condensed consolidated balance sheets. Any changes in the fair value of our available-for-sale securities, that do not result in recognition or reversal of an allowance for credit loss or write-down, are recorded, net of taxes, as a component of accumulated other comprehensive income or loss on our condensed consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of marketable securities are determined on a specific identification basis. Realized gains and losses, interest income and the amortization/accretion of premiums/discounts are included in other income/(expense), net, on our condensed consolidated statements of operations and comprehensive income. Interest receivable is recorded in prepaid expenses and other current assets on our condensed consolidated balance sheets. We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is expected, the loss will be recognized on an allowance basis, consistent with ASC 326-30, in our condensed consolidated statement of operations and comprehensive income in the period the determination is made.
Fair Value Measurements	Fair Value Measurements Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis Fair value is defined as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or the liability in an orderly transaction between market participants on the measurement date. Additionally, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable inputs. The level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Our assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories: Level 1—quoted prices (unadjusted) in active markets for identical assets and liabilities; Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; and Level 3—unobservable inputs in which there is little or no market data available, which require the reporting entity to use significant unobservable inputs or valuation techniques. Assets and Liabilities That Are Measured at Fair Value on a Nonrecurring Basis The purchase price of business acquisitions is primarily allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition date, with the excess recorded as goodwill. We utilize Level 3 inputs in the determination of the initial fair value. Contingent consideration represents contingent milestone, performance and revenue-sharing payment obligations related to business acquisitions and is measured at fair value, based on significant inputs that are not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions we believe would be made by a market participant. We assess these assumptions on an ongoing basis as additional data impacting the assumptions is obtained. The fair value of contingent consideration recorded in business acquisition liabilities on our condensed consolidated balance sheets, and changes in the fair value of contingent consideration are recognized within acquisition related costs in the condensed consolidated statements of operations and comprehensive income. The fair value of contingent restricted stock unit (“RSU”) grants are recorded as additional paid-in capital in the consolidated balance sheet on the day of the grant due to the remote likelihood of forfeiture.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The majority of our inventory is finished goods and we utilize both in-house manufacturing and third-party suppliers to produce our products. We periodically evaluate the carrying value of our inventories in relation to estimated forecasts of product demand, which takes into consideration the life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a write-down for such excess inventories. Once inventory has been written down, it creates a new cost basis for inventory that is not subsequently written up.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill represents the excess of purchase price over the fair values of the identifiable assets acquired less the liabilities assumed in the acquisition of a business. Goodwill is tested for impairment at least annually or whenever events or circumstances indicate that a carrying amount may not be recoverable. Goodwill is tested for impairment at the reporting unit level by comparing the reporting unit’s carrying amount to the fair value of the reporting unit. Fair values are estimated using an income and discounted cash flow approach. We perform our annual impairment test of goodwill in the fourth quarter of each year. We consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. During the nine months ended September 30, 2021 and 2020, we did not record any impairment charges related to goodwill. Intangible assets consist of purchased in-process research and development (“IPR&D”), developed technology, supplier network, patents, customer relationships, re-acquired rights, and non-compete agreements. Intangible assets with finite useful lives are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from one to sixteen years. Intangible assets are tested for impairment annually or whenever events or circumstances indicate that a carrying amount of an asset (asset group) may not be recoverable. If an impairment is indicated, we measure the amount of the impairment loss as the amount by which the carrying amount exceeds the fair value of the asset. Fair value is generally determined using a discounted future cash flow analysis. There were no impairments of finite-lived intangible assets during the nine months ended September 30, 2021 or 2020. IPR&D has an indefinite life and is not amortized until completion of the project at which time the IPR&D becomes an amortizable asset. If the related project is not completed in a timely manner, we may have an impairment related to the IPR&D, calculated as the excess of the asset’s carrying value over its fair value. There were no impairments of IPR&D during the nine months ended September 30, 2021 or 2020.
Stock-Based Compensation	Stock-Based Compensation The cost of employee and non-employee director awards is measured at the grant date fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period of the equity award. Compensation expense for awards includes the impact of forfeiture in the period when they occur. We estimate the fair value of stock options utilizing the Black-Scholes option-pricing model. Inputs to the Black-Scholes model include our stock price, expected volatility, expected term, risk-free interest rate and expected dividends. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options offering period which is derived from historical experience. The risk-free interest rate assumption is based on observed interest rates of U.S. Treasury securities appropriate for the expected terms of the stock options. The dividend yield assumption is based on the history and expectation of no dividend payouts. The fair value of restricted stock units is estimated using the closing price of the Company’s common stock on the date of grant.
Recently Issued Accounting Pronouncements & Recently Adopted Accounting Pronouncements	Recently Issued Accounting Pronouncements On March 12, 2020, the FASB issued ASU No. 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is effective for all entities as of March 12, 2020, and will apply through December 31, 2022. To date, we have had no impacts on our investment portfolio or our credit agreement with Citizens Bank, N.A. related to reference rate reform. We will continue to evaluate the impact this guidance could have on our condensed consolidated financial statements and related disclosures. (l) Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. We adopted ASU 2019-12 on January 1, 2021. This standard did not have a material impact on our financial position, results of operations and disclosures.

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2021	Nov. 02, 2021
Document and Entity Information [Abstract]
Document Quarterly Report	true
Document Transition Report	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2021
Entity Registrant Name	GLOBUS MEDICAL, INC.
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Class A Common Stock, par value $.001 per share
Trading Symbol	GMED
Security Exchange Name	NYSE
Entity File Number	001-35621
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3744954
Entity Address, Address Line One	2560 General Armistead Avenue
Entity Address, City or Town	Audubon
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19403
City Area Code	610
Local Phone Number	930-1800
Amendment Flag	false
Entity Common Stock, Shares Outstanding		101,470,823
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001237831
Current Fiscal Year End Date	--12-31

DEBT

9 Months Ended

Sep. 30, 2021

DEBT [Abstract]

Debt

NOTE 11. DEBT

Line of Credit

In August 2020, we entered into a credit agreement with Citizens Bank, N.A. (the “Credit Agreement”) that provides a revolving credit facility permitting borrowings up to $125.0 million (the “Revolving Credit Facility”). As amended, the Credit Agreement has a termination date of August 3, 2022. The Revolving Credit Facility includes up to a $25.0 million sub limit for letters of credit. Revolving loans under the Credit Agreement will bear interest, at the Company’s option, at either a base rate or the Adjusted LIBOR Rate (as defined in the Credit Agreement), plus, in each case, an applicable margin, as determined in accordance with the provisions of the Credit Agreement. The base rate will be the highest of: the rate of interest announced publicly by Citizens Bank, N.A. from time to time as its “prime rate”; the federal funds effective rate plus 1/2 of 1%; and the Adjusted LIBOR Rate for a one-month period plus 1%. The applicable margin is subject to adjustment as provided in the Credit Agreement. The Credit Agreement contains financial and other customary covenants, including a maximum leverage ratio. As of September 30, 2021, we have not borrowed under the Credit Agreement with Citizens Bank, N.A.

STOCK-BASED COMPENSATION

9 Months Ended

Sep. 30, 2021

STOCK-BASED COMPENSATION [Abstract]

Stock-Based Compensation

NOTE 13. STOCK-BASED COMPENSATION

We have three stock plans: our 2008 Stock Plan, our 2012 Equity Incentive Plan (the “2012 Plan”), and our 2021 Equity Incentive Plan (the “2021 Plan”). The 2021 Plan is the only active stock plan. The purpose of the 2008 and 2012 Stock Plans was, and of the 2021 Plan is, to provide incentive to employees, directors, and consultants of Globus. The Plans are administered by the Board of Directors of Globus (the “Board”) or its delegates. The number, type of option, exercise price, and vesting terms are determined by the Board or its delegates in accordance with the terms of the Plans. The options granted expire on a date specified by the Board, which is generally not more than ten years from the grant date. Options granted to employees generally vest in varying installments over a four-year period.

The 2012 Plan was approved by our Board in March 2012, and by our stockholders in June 2012. Under the 2012 Plan, the aggregate number of shares of Class A Common stock that were able to be issued subject to options and other awards is equal to the sum of (i) 3,076,923 shares, (ii) any shares available for issuance under the 2008 Plan as of March 13, 2012, (iii) any shares underlying awards outstanding under the 2008 Plan as of March 13, 2012 that, on or after that date, are forfeited, terminated, expired or lapse for any reason, or are settled for cash without delivery of shares and (iv) starting January 1, 2013, an annual increase in the number of shares available under the 2012 Plan equal to up to 3% of the number of shares of our common and preferred stock outstanding at the end of the previous year, as determined by our Board. The number of shares that were able to be issued or transferred pursuant to incentive stock options under the 2012 Plan was limited to 10,769,230 shares. The shares of Class A Common stock covered by the 2012 Plan included authorized but unissued shares, treasury shares or shares of common stock purchased on the open market.

The 2021 Plan was approved by our Board in March 2021, and by our stockholders in June 2021. Under the 2021 Plan, the aggregate number of shares of Class A Common stock that were able to be issued subject to options and other awards is equal to the sum of (i) 2,000,000 shares, (ii) any shares available for issuance under the 2012 Plan as of June 3, 2021 and (iii) any shares underlying awards outstanding under the 2012 Plan or 2021 Plan as of June 3, 2021 that, on or after that date, are forfeited, terminated, expired or lapse for any reason, or are settled for cash without delivery of shares. The number of shares that may be issued or transferred pursuant to incentive stock options under the 2021 Plan is limited to 2,000,000 shares. The shares of Class A Common stock covered by the 2021 Plan include authorized but unissued shares, treasury shares or shares of common stock purchased on the open market.

As of September 30, 2021, pursuant to the 2021 Plan, there were 2,845,575 shares of Class A Common stock reserved and 2,684,008 shares of Class A Common stock available for future grants.

Stock Options

Stock option activity during the nine months ended September 30, 2021 is summarized as follows:



	Option ‎Shares (thousands)	Weighted ‎average ‎exercise ‎price		Weighted ‎average ‎remaining ‎contractual ‎life (years)	Aggregate ‎intrinsic ‎value ‎(thousands)
Outstanding at December 31, 2020	9,746	$	41.33
Granted	1,925		67.68
Exercised	(1,746)		34.38
Forfeited	(521)		51.64
Outstanding at September 30, 2021	9,404	$	47.44	7.2	$	275,662
Exercisable at September 30, 2021	4,439	$	38.61	6.0	$	168,709
Expected to vest at September 30, 2021	4,965	$	55.34	8.2	$	106,953

The total intrinsic value of stock options exercised was $33.8 million and $23.3 million during the three months ended September 30, 2021, and 2020, respectively. The total intrinsic value of stock options exercised was $68.9 million and $39.4 million during the nine months ended September 30, 2021, and 2020, respectively.

The fair value of the options was estimated on the date of the grant using a Black-Scholes option pricing model with the following assumptions:


	Nine Months Ended
	September 30,
	2021			2020
Risk-free interest rate	0.40%	-	0.84%	0.23%	-	1.67%
Expected term (years)	4.8			4.9
Expected volatility	33.0%	-	34.0%	28.0%	-	37.0%
Expected dividend yield		—%			—%

The weighted average grant date fair value of stock options granted during the three months ended September 30, 2021, and 2020 was $24.11 and $16.98 per share, respectively. The weighted average grant date fair value of stock options granted during the nine months ended September 30, 2021, and 2020 was $20.19 and $14.54 per share, respectively.

Restricted Stock Units

Restricted stock unit activity during the nine months ended September 30, 2021 is summarized as follows:


	Restricted Stock ‎Units (thousands)	Weighted ‎average ‎grant date fair value ‎per share		Weighted ‎average ‎remaining ‎contractual ‎life (years)
Outstanding at December 31, 2020	3	$	58.69
Granted	23		74.87
Vested	—		—
Forfeited	—		—
Outstanding at September 30, 2021	26	$	72.81	9.0

Stock-Based Compensation

Compensation expense related to stock options granted to employees and non-employees under the Plans was as follows:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
Stock-based compensation expense	$	7,451	$	7,020	$	22,781	$	21,138
Net stock-based compensation capitalized into inventory		170		(13)		511		197
Total stock-based compensation cost	$	7,621	$	7,007	$	23,292	$	21,335

As of September 30, 2021, there was $66.1 million of unrecognized compensation expense related to unvested employee stock options that are expected to vest over a weighted average period of approximately three years.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2021

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Summary Of Significant Accounting Policies

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of Presentation

The accompanying interim unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2020.

In the opinion of management, these condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position as of September 30, 2021, and results of operations for the three and nine months ended September 30, 2021. The results of operations for any interim period may not be indicative of results for the full year.

(b) Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of Globus and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are determined to be necessary.

Significant areas that require estimates include revenue recognition, intangible assets, business acquisition liabilities, allowance for doubtful accounts, stock-based compensation, reserves for excess and obsolete inventory, useful lives of assets, the outcome of litigation, recoverability of intangible assets and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.

(d) Revenue Recognition

Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. Sales and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. For purposes of disclosure, we disaggregate our revenue into two categories, Musculoskeletal Solutions and Enabling Technologies. Our Musculoskeletal Solutions products consist primarily of the implantable devices, disposables, and unique instruments used in an expansive range of spine, orthopedic trauma, hip, knee and extremity procedures. The majority of contracts with our customers for Musculoskeletal Solutions products have a single performance obligation and revenue is recognized at a point in time. Our Enabling Technologies products are advanced robotics hardware systems and related technologies that are designed to enhance a surgeon’s capabilities and streamline surgical procedures by making them less invasive, more accurate, and more reproducible to improve patient care. The majority of contracts with our customers for Enabling Technologies products contain multiple performance obligations, including maintenance and support, and revenue is recognized as we fulfill each performance obligation. When contracts have multiple performance obligations, we allocate the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold.

Nature of Products and Services

A significant portion of our Musculoskeletal Solutions product revenue is generated from consigned inventory maintained at hospitals or with sales representatives. Revenue from the sale of consigned musculoskeletal products is recognized when we transfer control, which generally occurs at the time the product is used or implanted. For all other Musculoskeletal Solutions product transactions, we recognize revenue when we transfer title to the goods, provided there are no remaining performance obligations that can affect the customer’s final acceptance of the sale.

Revenue from the sale of Enabling Technologies products is generally recognized when control transfers to the customer which occurs at the time the product is shipped or delivered. Any revenue related to the provision of maintenance and support is recognized as we satisfy the performance obligation. We use an observable price to determine the stand-alone selling price for each separate performance obligation.

Contract Balances

Timing of revenue recognition may differ from the timing of invoicing to customers. We record a receivable when revenue is recognized prior to invoicing, or deferred revenue when revenue is recognized subsequent to invoicing.

Deferred revenue is comprised mainly of unearned revenue related to the sales of certain Enabling Technologies products, which includes maintenance and support services. Maintenance and support services are generally invoiced annually, at the beginning of each contract period, and revenue is recognized ratably over the maintenance period. For the three and nine months ended September 30, 2021, there was an immaterial amount of revenue recognized from previously deferred revenue.

(e) Cash, Cash Equivalents, and Restricted Cash

The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. Cash equivalents, which consist of money market accounts, commercial paper and corporate debt securities are stated at fair value.

(f) Marketable Securities

Our marketable securities include municipal bonds, corporate debt securities, commercial paper, asset-backed securities, and securities of government, federal agency, and other sovereign obligations are classified as available-for-sale as of September 30, 2021. Short-term and long-term marketable securities are recorded at fair value on our condensed consolidated balance sheets. Any changes in the fair value of our available-for-sale securities, that do not result in recognition or reversal of an allowance for credit loss or write-down, are recorded, net of taxes, as a component of accumulated other comprehensive income or loss on our condensed consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of marketable securities are determined on a specific identification basis. Realized gains and losses, interest income and the amortization/accretion of premiums/discounts are included in other income/(expense), net, on our condensed consolidated statements of operations and comprehensive income. Interest receivable is recorded in prepaid expenses and other current assets on our condensed consolidated balance sheets.

We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is expected, the loss will be recognized on an allowance basis, consistent with ASC 326-30, in our condensed consolidated statement of operations and comprehensive income in the period the determination is made.

(g) Fair Value Measurements

Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis

Fair value is defined as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or the liability in an orderly transaction between market participants on the measurement date. Additionally, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable inputs. The level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

Our assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:

Level 1—quoted prices (unadjusted) in active markets for identical assets and liabilities;

Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; and

Level 3—unobservable inputs in which there is little or no market data available, which require the reporting entity to use significant unobservable inputs or valuation techniques.

Assets and Liabilities That Are Measured at Fair Value on a Nonrecurring Basis

The purchase price of business acquisitions is primarily allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the acquisition date, with the excess recorded as goodwill. We utilize Level 3 inputs in the determination of the initial fair value.

Contingent consideration represents contingent milestone, performance and revenue-sharing payment obligations related to business acquisitions and is measured at fair value, based on significant inputs that are not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions we believe would be made by a market participant. We assess these assumptions on an ongoing basis as additional data impacting the assumptions is obtained. The fair value of contingent consideration recorded in business acquisition liabilities on our condensed consolidated balance sheets, and changes in the fair value of contingent consideration are recognized within acquisition related costs in the condensed consolidated statements of operations and comprehensive income. The fair value of contingent restricted stock unit (“RSU”) grants are recorded as additional paid-in capital in the consolidated balance sheet on the day of the grant due to the remote likelihood of forfeiture.

(h) Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The majority of our inventory is finished goods and we utilize both in-house manufacturing and third-party suppliers to produce our products. We periodically evaluate the carrying value of our inventories in relation to estimated forecasts of product demand, which takes into consideration the life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a write-down for such excess inventories. Once inventory has been written down, it creates a new cost basis for inventory that is not subsequently written up.

(i) Goodwill and Intangible Assets

Goodwill represents the excess of purchase price over the fair values of the identifiable assets acquired less the liabilities assumed in the acquisition of a business. Goodwill is tested for impairment at least annually or whenever events or circumstances indicate that a carrying amount may not be recoverable. Goodwill is tested for impairment at the reporting unit level by comparing the reporting unit’s carrying amount to the fair value of the reporting unit. Fair values are estimated using an income and discounted cash flow approach. We perform our annual impairment test of goodwill in the fourth quarter of each year. We consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. During the nine months ended September 30, 2021 and 2020, we did not record any impairment charges related to goodwill.

Intangible assets consist of purchased in-process research and development (“IPR&D”), developed technology, supplier network, patents, customer relationships, re-acquired rights, and non-compete agreements. Intangible assets with finite useful lives are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from one to sixteen years. Intangible assets are tested for impairment annually or whenever events or circumstances indicate that a carrying amount of an asset (asset group) may not be recoverable. If an impairment is indicated, we measure the amount of the impairment loss as the amount by which the carrying amount exceeds the fair value of the asset. Fair value is generally determined using a discounted future cash flow analysis. There were no impairments of finite-lived intangible assets during the nine months ended September 30, 2021 or 2020.

IPR&D has an indefinite life and is not amortized until completion of the project at which time the IPR&D becomes an amortizable asset. If the related project is not completed in a timely manner, we may have an impairment related to the IPR&D, calculated as the excess of the asset’s carrying value over its fair value. There were no impairments of IPR&D during the nine months ended September 30, 2021 or 2020.

(j) Stock-Based Compensation

The cost of employee and non-employee director awards is measured at the grant date fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period of the equity award. Compensation expense for awards includes the impact of forfeiture in the period when they occur.

We estimate the fair value of stock options utilizing the Black-Scholes option-pricing model. Inputs to the Black-Scholes model include our stock price, expected volatility, expected term, risk-free interest rate and expected dividends. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options offering period which is derived from historical experience. The risk-free interest rate assumption is based on observed interest rates of U.S. Treasury securities appropriate for the expected terms of the stock options. The dividend yield assumption is based on the history and expectation of no dividend payouts. The fair value of restricted stock units is estimated using the closing price of the Company’s common stock on the date of grant.

(k) Recently Issued Accounting Pronouncements

On March 12, 2020, the FASB issued ASU No. 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is effective for all entities as of March 12, 2020, and will apply through December 31, 2022. To date, we have had no impacts on our investment portfolio or our credit agreement with Citizens Bank, N.A. related to reference rate reform. We will continue to evaluate the impact this guidance could have on our condensed consolidated financial statements and related disclosures.

(l) Recently Adopted Accounting Pronouncements

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. We adopted ASU 2019-12 on January 1, 2021. This standard did not have a material impact on our financial position, results of operations and disclosures.

INCOME TAXES (Tables)

9 Months Ended

Sep. 30, 2021

INCOME TAXES [Abstract]

Reconciliation of Statutory U.S. Federal Tax Rate to Effective Rate


	Three Months Ended		Nine Months Ended
	September 30,		September 30,
	2021	2020	2021	2020
Effective income tax rate	13.3%	16.8%	16.5%	22.5%

PROPERTY AND EQUIPMENT

9 Months Ended

Sep. 30, 2021

PROPERTY AND EQUIPMENT [Abstract]

PROPERTY AND EQUIPMENT

NOTE 8. PROPERTY AND EQUIPMENT

Property and equipment included the following:



	Useful	September 30,		December 31,
(In thousands)	Life	2021		2020
Land	—	$	8,308	$	8,322
Buildings and improvements	31.5		44,497		33,825
Equipment	5-15		112,776		102,553
Instruments	5		285,730		278,930
Modules and cases	5		43,422		41,919
Other property and equipment	3-5		22,095		27,781
			516,828		493,330
Less: accumulated depreciation			(301,163)		(276,451)
Total		$	215,665	$	216,879

Instruments are hand-held devices used by surgeons to install implants during surgery. Modules and cases are used to store and transport the instruments and implants.

Depreciation expense related to property and equipment was as follows:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
Depreciation	$	12,178	$	12,148	$	39,068	$	33,925

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2021

FAIR VALUE MEASUREMENTS [Abstract]

Fair Value Measurements

NOTE 6. FAIR VALUE MEASUREMENTS

Assets and liabilities measured at fair value on a recurring basis included the following:



(In thousands)	Balance at September 30, 2021		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	42,561	$	38,386	$	4,175	$	—
Municipal bonds		126,120		—		126,120		—
Corporate debt securities		313,998		—		313,998		—
Commercial paper		16,994		—		16,994		—
Asset-backed securities		155,913		—		155,913		—
Government, federal agency, and other sovereign obligations		10,108		—		10,108		—
Liabilities:
Business acquisition liabilities		57,842		—		—		57,842



(In thousands)	Balance at December 31, 2020		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	56,223	$	23,628	$	32,595	$	—
Municipal bonds		110,612		—		110,612		—
Corporate debt securities		260,334		—		260,334		—
Commercial paper		25,547		—		25,547		—
Asset-backed securities		141,426		—		141,426		—
Government, federal agency, and other sovereign obligations		7,947		—		7,947		—
Liabilities:
Business acquisition liabilities		37,270		—		—		37,270

Our marketable securities are classified as Level 2 within the fair value hierarchy, as we measure their fair value using market prices for similar instruments and inputs such as actual trade data, benchmark yields, broker/dealer quotes and other similar data obtained from quoted market prices or independent pricing vendors.

Assets and Liabilities That Are Measured at Fair Value on a Nonrecurring Basis

Fair value of the revenue-based business acquisition liabilities was determined using a discounted cash flow model and an option pricing model. The significant inputs of such models are not observable in the market, such as certain financial metric growth rates, volatility and discount rates, market price risk adjustment, projections associated with the applicable milestone, the interest rate, and the related probabilities and payment structure in the contingent consideration arrangement.

The following are the significant unobservable inputs used in the two valuation techniques:


Unobservable input	Range			Weighted Average*
Revenue risk premium	2.5%	-	4.9%	3.1%
Revenue volatility	14.0%	-	15.8%	14.6%
Discount rate	1.0%	-	8.5%	3.3%
Projected year of payment	2021	-	2031

* The weighted average rates were calculated based on the relative fair value of each business acquisition liability.

The change in the carrying value of the business acquisition liabilities during the three and nine months ended September 30, 2021 and 2020, respectively included the following:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2021		2020		2021		2020
Fair value measurement at beginning of period	$	47,995	$	4,216	$	37,270	$	9,549
Purchase price contingent consideration		12,628		—		12,628		—
Contingent cash payments		(1,613)		(175)		(4,628)		(1,028)
Contingent RSU grants		(1,311)		—		(1,671)		—
Changes in fair value of business acquisition liabilities		208		507		14,336		970
Contractual payable reclassification		(65)		—		(93)		(4,943)
Fair value measurement at September 30, 2021 and 2020, respectively	$	57,842	$	4,548	$	57,842	$	4,548

Changes in the fair value of business acquisition liabilities are driven by changes in market conditions and the achievement of certain performance conditions.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

INVENTORIES

9 Months Ended

Sep. 30, 2021

INVENTORIES [Abstract]

Inventories

NOTE 7. INVENTORIES

Inventories included the following:



	September 30,		December 31,
(In thousands)	2021		2020
Raw materials	$	44,038	$	39,646
Work in process		18,274		16,446
Finished goods		172,056		173,061
Total inventories	$	234,368	$	229,153

During the three months ended September 30, 2021 and 2020, net adjustments to cost of sales related to excess and obsolete inventory were $0.6 million and $5.2 million, respectively. The net adjustments for the three months ended September 30, 2021 and 2020 reflect a combination of additional expense for excess and obsolete related provisions ($3.8 million and $7.9 million, respectively) offset by sales and disposals ($3.2 million and $2.7 million, respectively) of inventory for which an excess and obsolete provision was provided previously through expense recognized in prior periods.

During the nine months ended September 30, 2021 and 2020, net adjustments to cost of sales related to excess and obsolete inventory were $5.6 million and $12.4 million, respectively. The net adjustments for the nine months ended September 30, 2021 and 2020 reflect a combination of additional expense for excess and obsolete related provisions ($15.2 million and $18.9 million, respectively) offset by sales and disposals ($9.6 million and $6.5 million, respectively) of inventory for which an excess and obsolete provision was provided previously through expense recognized in prior periods.

GOODWILL AND INTANGIBLE ASSETS (Summary of Goodwill) (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
GOODWILL AND INTANGIBLE ASSETS [Abstract]
Goodwill, Beginning Balance	$ 156,716	$ 128,775
Additions and adjustments	10,977	26,043
Foreign exchange	(1,115)	1,898
Goodwill, Ending Balance	$ 166,578	$ 156,716

Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Condensed Consolidated Statements of Operations and Comprehensive Income [Abstract]
Net sales	$ 229,721	$ 216,098	$ 708,081	$ 555,597
Cost of goods sold	58,554	57,097	177,427	156,604
Gross profit	171,167	159,001	530,654	398,993
Operating expenses:
Research and development	15,853	14,421	46,324	69,278
Selling, general and administrative	96,444	89,152	301,589	262,710
Provision for litigation	605		511	197
Amortization of intangibles	4,573	4,152	13,970	12,043
Acquisition related costs	363	1,263	14,507	1,867
Total operating expenses	117,838	108,988	376,901	346,095
Operating income/(loss)	53,329	50,013	153,753	52,898
Other income/(expense), net:
Interest income/(expense), net	2,105	3,085	7,358	10,999
Foreign currency transaction gain/(loss)	(898)	(170)	(969)	(806)
Other income/(expense)	(84)	202	437	595
Total other income/(expense), net	1,123	3,117	6,826	10,788
Income/(loss) before income taxes	54,452	53,130	160,579	63,686
Income tax provision	7,241	8,914	26,494	14,358
Net income/(loss)	47,211	44,216	134,085	49,328
Other comprehensive income/(loss):
Unrealized gain/(loss) on marketable securities, net of tax	(991)	(770)	(3,431)	2,285
Foreign currency translation gain/(loss)	(491)	1,679	(3,578)	2,820
Total other comprehensive income/(loss)	(1,482)	909	(7,009)	5,105
Comprehensive income/(loss)	$ 45,729	$ 45,125	$ 127,076	$ 54,433
Earnings per share:
Basic	$ 0.47	$ 0.45	$ 1.33	$ 0.50
Diluted	$ 0.45	$ 0.44	$ 1.30	$ 0.49
Weighted average shares outstanding:
Basic	101,104	98,217	100,477	98,453
Diluted	104,418	100,485	103,430	100,823

STOCK-BASED COMPENSATION (Fair Value of Options Using Black Scholes Option Pricing Model) (Details)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
STOCK-BASED COMPENSATION [Abstract]
Risk-free interest rate, minimum	0.40%	0.23%
Risk-free interest rate, maximum	0.84%	1.67%
Expected term (years)	4 years 9 months 18 days	4 years 10 months 24 days
Expected volatility, minimum	33.00%	28.00%
Expected volatility, maximum	34.00%	37.00%
Expected dividend yield

ACCRUED EXPENSES (Tables)

9 Months Ended

Sep. 30, 2021

ACCRUED EXPENSES [Abstract]

Schedule of Accrued Expenses

Accrued expense included the following:



	September 30,		December 31,
(In thousands)	2021		2020
Compensation and other employee-related costs	$	48,672	$	44,948
Legal and other settlements and expenses		604		650
Accrued non-income taxes		5,659		4,952
Royalties		3,821		3,720
Rebates & Fees		7,759		8,011
Other		14,965		16,053
Total accrued expenses	$	81,480	$	78,334

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2021

COMMITMENTS AND CONTINGENCIES [Abstract]

Commitments and Contingencies

NOTE 15. COMMITMENTS AND CONTINGENCIES

We are involved in a number of proceedings, legal actions, and claims arising in the ordinary course of business. Such matters are subject to many uncertainties, and the outcomes of these matters are not within our control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, including injunctions prohibiting us from engaging in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. We record a liability in the condensed consolidated financial statements for these actions when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount in the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not probable, and the amount can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss. While it is not possible to predict the outcome for most of the matters discussed, we believe it is possible that costs associated with them could have a material adverse impact on our consolidated earnings, financial position or cash flows.

Moskowitz Family LLC Litigation

On November 20, 2019, Moskowitz Family LLC filed suit against us in the U.S. District Court for the Western District of Texas for patent infringement. Moskowitz, a non-practicing entity, alleges that Globus willfully infringes one or more claims of eight patents by making, using, offering for sale or selling the COALITION^®, COALITION MIS^®, COALITION AGX^®, CORBEL^TM, MONUMENT^®, MAGNIFY^®-S, HEDRON IA^TM, HEDRON IC^TM, INDEPENDENCE^®, INDEPENDENCE MIS^®, INDEPENDENCE MIS AGX^®, FORTIFY^®and XPAND^® families, SABLE^TM, RISE^®, RISE^® INTRALIF, RISE^®-L, ELSA^®, ELSA^® ATP, RASS, ALTERA^®, ARIEL^®, LATIS^®, CALIBER^® and CALIBER^®-L products. Moskowitz seeks an unspecified amount in damages and injunctive relief. On July 2, 2020, this suit was transferred from the U.S. District Court for the Western District of Texas to the U.S. District Court for the Eastern District of Pennsylvania. The outcome of this litigation cannot be determined, nor can we estimate a range of potential loss, therefore, we have not recorded a liability related to this litigation as of September 30, 2021.

MARKETABLE SECURITIES (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Payable to brokers		$ 9.3
Short-term Investments [Member] \| Maximum [Member]
Debt Securities, Available-for-sale [Line Items]
Contractual Maturity	1 year	1 year
Long-term Investments [Member] \| Minimum [Member]
Debt Securities, Available-for-sale [Line Items]
Contractual Maturity	1 year	1 year
Long-term Investments [Member] \| Maximum [Member]
Debt Securities, Available-for-sale [Line Items]
Contractual Maturity	3 years	3 years

BACKGROUND (Narrative) (Details)	Sep. 30, 2021 item
Minimum [Member]
Number of products launched	220

GOODWILL AND INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2021

GOODWILL AND INTANGIBLE ASSETS [Abstract]

Summary of Goodwill



(In thousands)
December 31, 2019	$	128,775
Additions and adjustments		26,043
Foreign exchange		1,898
December 31, 2020		156,716
Foreign exchange		(1,115)
Additions and adjustments		10,977
September 30, 2021	$	166,578

Summary of Intangible Assets



		September 30, 2021
(In thousands)	Weighted Average Amortization Period (in years)	Gross ‎Carrying ‎Amount		Accumulated ‎Amortization		Intangible ‎Assets, ‎net
Supplier network	10.0	$	4,000	$	(2,767)	$	1,233
Customer relationships & other intangibles	6.5		57,090		(36,724)		20,366
Developed technology	8.0		71,815		(26,152)		45,663
Patents	16.1		8,910		(3,077)		5,833
Total intangible assets		$	141,815	$	(68,720)	$	73,095



		December 31, 2020
(In thousands)	Weighted Average Amortization Period (in years)	Gross ‎Carrying ‎Amount		Accumulated ‎Amortization		Intangible ‎Assets, ‎net
Supplier network	10.0	$	4,000	$	(2,467)	$	1,533
Customer relationships & other intangibles	6.5		57,704		(32,056)		25,648
Developed technology	8.0		72,644		(19,295)		53,349
Patents	16.1		9,082		(2,663)		6,419
Total intangible assets		$	143,430	$	(56,481)	$	86,949

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense



(In thousands)	Annual ‎Amortization
Remaining 2021	$	4,602
2022		18,260
2023		16,157
2024		13,162
2025		8,876
Thereafter		12,038
Total	$	73,095

GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2021

GOODWILL AND INTANGIBLE ASSETS [Abstract]

Goodwill and Intangible Assets

NOTE 9. GOODWILL AND INTANGIBLE ASSETS

The change in the carrying amount of goodwill during the twelve months ended December 31, 2020 and the nine months ended September 30, 2021, respectively included the following:



(In thousands)
December 31, 2019	$	128,775
Additions and adjustments		26,043
Foreign exchange		1,898
December 31, 2020		156,716
Foreign exchange		(1,115)
Additions and adjustments		10,977
September 30, 2021	$	166,578

The composition of intangible assets was as follows:



		September 30, 2021
(In thousands)	Weighted Average Amortization Period (in years)	Gross ‎Carrying ‎Amount		Accumulated ‎Amortization		Intangible ‎Assets, ‎net
Supplier network	10.0	$	4,000	$	(2,767)	$	1,233
Customer relationships & other intangibles	6.5		57,090		(36,724)		20,366
Developed technology	8.0		71,815		(26,152)		45,663
Patents	16.1		8,910		(3,077)		5,833
Total intangible assets		$	141,815	$	(68,720)	$	73,095



		December 31, 2020
(In thousands)	Weighted Average Amortization Period (in years)	Gross ‎Carrying ‎Amount		Accumulated ‎Amortization		Intangible ‎Assets, ‎net
Supplier network	10.0	$	4,000	$	(2,467)	$	1,533
Customer relationships & other intangibles	6.5		57,704		(32,056)		25,648
Developed technology	8.0		72,644		(19,295)		53,349
Patents	16.1		9,082		(2,663)		6,419
Total intangible assets		$	143,430	$	(56,481)	$	86,949

The following table summarizes amortization of intangible assets for future periods as of September 30, 2021:



(In thousands)	Annual ‎Amortization
Remaining 2021	$	4,602
2022		18,260
2023		16,157
2024		13,162
2025		8,876
Thereafter		12,038
Total	$	73,095

ASSET ACQUISITIONS AND BUSINESS COMBINATIONS (Narrative) (Details) $ in Thousands	3 Months Ended					9 Months Ended
	Sep. 30, 2021 USD ($) item	Dec. 31, 2020 USD ($) item	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)
Business Acquisition [Line Items]
Goodwill	$ 166,578	$ 156,716					$ 128,775
Acquired in-process research and development						$ 24,418
Synoste Acquisition [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net				$ 25,300
Payments to Acquire Businesses, Gross				$ 22,800
Business Acquisitions, Contractual Holdback Obligation Payable Period				18 months
Acquired in-process research and development				$ 24,400
Liabilities incurred from acquisition				2,500
Synoste Acquisition [Member] \| Third Anniversary [Member]
Business Acquisition [Line Items]
Contingent consideration liability				8,000
Synoste Acquisition [Member] \| Fourth Anniversary [Member]
Business Acquisition [Line Items]
Contingent consideration liability				$ 4,000
StelKast Acquisition [Member]
Business Acquisition [Line Items]
Inventory acquired					$ 15,300
Property, plant and equipment acquired					4,200
Intangible assets acquired					3,900
Payments to Acquire Businesses, Gross					23,800
Goodwill, Acquired During Period					4,700
Business combination, consideration transferred					28,100
Contingent consideration liability					$ 4,300
Contingent consideration payment			$ 5,000
Two Acquisitions [Member]
Business Acquisition [Line Items]
Number of acquisitions \| item	2	2
Business combination, performance obligation period	10 years	10 years
Intangible assets acquired	$ 1,600	$ 8,800
Weighted average amortization period	3 years 9 months 18 days	4 years 2 months 12 days
Business combination, consideration transferred	$ 12,600	$ 1,500
Contingent consideration liability		33,200
Goodwill	$ 11,000	26,200
Liabilities incurred from acquisition		$ 300

LEASES (Future Minimum Lease Payments) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
LEASES [Abstract]
Remaining 2021	$ 607
2022	2,169
2023	1,452
2024	987
2025	396
Thereafter	153
Total undiscounted operating lease payments	5,764
Less : imputed interest	339
Total operating lease liability	$ 5,425	$ 4,801

FAIR VALUE MEASUREMENTS (Significant Unobservable Inputs in Valuation Techniques) (Details) - Fair Value, Inputs, Level 3 [Member]

9 Months Ended

Sep. 30, 2021

Maximum [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Projected year of payment

2031

Minimum [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Projected year of payment

2021

Revenue Risk Premium [Member] | Maximum [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business acquisition liabilities, measurement input

4.9

Revenue Risk Premium [Member] | Minimum [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business acquisition liabilities, measurement input

2.5

Revenue Risk Premium [Member] | Weighted Average [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business acquisition liabilities, measurement input

3.1

^[1]

Revenue Volatility [Member] | Maximum [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business acquisition liabilities, measurement input

15.8

Revenue Volatility [Member] | Minimum [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business acquisition liabilities, measurement input

14.0

Revenue Volatility [Member] | Weighted Average [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business acquisition liabilities, measurement input

14.6

^[1]

Discount Rate [Member] | Maximum [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business acquisition liabilities, measurement input

8.5

Discount Rate [Member] | Minimum [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business acquisition liabilities, measurement input

1.0

Discount Rate [Member] | Weighted Average [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business acquisition liabilities, measurement input

3.3

^[1]

[1]	The weighted average rates were calculated based on the relative fair value of each business acquisition liability.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Goodwill impairment	$ 0	$ 0
Impairment of finite-lived intangible assets	0	0
Impairment of intangible assets	$ 0	$ 0

LEASES (Operating Lease Expense Recognized) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
LEASES [Abstract]
Operating lease expense	$ 783	$ 904	$ 2,461	$ 2,652

DEBT (Narrative) (Details) - USD ($)		9 Months Ended
DEBT (Narrative) (Details) - USD ($)	Aug. 06, 2020	Sep. 30, 2021
Citizens Bank [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity	$ 125,000,000.0
Line of credit facility, expiration date		Aug. 03, 2022
Line of credit, borrowed amount		$ 0
Federal Funds Effective Rate [Member]
Debt Instrument [Line Items]
Credit facility, basis spread on variable rate	0.50%
LIBOR [Member] \| Citizens Bank [Member]
Debt Instrument [Line Items]
Credit facility, basis spread on variable rate	1.00%
Letter of Credit [Member] \| Citizens Bank [Member]
Debt Instrument [Line Items]
Credit facility, maximum borrowing capacity	$ 25,000,000.0

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details